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Executive summary 
The marked increase of type 2 diabetes necessitates active development and 
implementation of efficient prevention programmes. A European-level action plan 
has been initiated in the launch of the IMAGE project to unify and improve the 
various prevention management concepts which currently exist within the EU. 
IMAGE stands for “Development and Implementation of a European Guideline 
and Training Standards for Diabetes Prevention”. In addition, to generate guidelines 
for prevention of type 2 diabetes and to develop a curriculum for the training of 
prevention managers, one aim of the project is to produce standards for quality 
management of diabetes prevention programmes. 
Even though quality indicators for clinical diabetes care have been developed 
by several organizations in different countries and continents, data are scarce on 
quality management of diabetes prevention programmes. Currently, programmes 
often lack methods for systematic follow-up and evaluation. This report describes 
the background and the methods used in the development of new quality indicators 
for diabetes primary prevention programmes. It is targeted at persons responsible 
for diabetes prevention at different levels within the health care systems.
Development of the quality indicators was conducted by a group of specialists 
representing different professional groups from several European countries. 
Indicators were produced by the expert group in consensus meetings and further 
developed by a subgroup of experts through combining evidence and expert 
opinion. The final approval and selection of the indicators used a stepwise approval 
process in which the participants of the other IMAGE working groups gave their 
comments on the quality indicators before the final selection was made.  
The quality indicators were generated to be applicable to the broadest possible 
population. The definition of high-risk population used here covers all subjects 
at risk for type 2 diabetes irrespective of the screening method used to identify 
these individuals. They are designed for adults, but not restricted to any specific age 
group within the adult population, and are applicable to both sexes. The indicators 
are linked to the IMAGE guidelines for data standards and are divided into two 
categories: quality and scientific outcome evaluation indicators. The quality 
indicators were developed for different prevention strategies: population-level 
prevention strategies, screening for high risk and high-risk prevention strategies. 
In total, 22 quality indicators were generated. They constitute the minimum level of 
quality assurance recommended for diabetes prevention programmes. In addition, 
20 scientific evaluation indicators with associated measurement standards were 
produced. These micro-level indicators describe the measurements which should 
be used if scientific analysis and reporting are planned. The measurement standards 
underline the importance of the high quality methodology needed to attain reliable 
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and comparable results. In addition to the indicators, audit and data collection 
forms were developed.
The working group hopes that these quality tools together with the IMAGE 
guidelines and the prevention manager curriculum will provide a useful apparatus 
for improving the quality of diabetes prevention in Europe, and make different 
prevention approaches comparable. 
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1 Objectives
The increase of type 2 diabetes is a major public health problem across the entire 
European Union (EU). Type 2 diabetes is increasing in prevalence, especially 
among working-age populations, but also in children and adolescents. Even if the 
prevalence of obesity were to remain stable until 2030, which seems unlikely, it is 
anticipated that the number of people with diabetes will more than double (1, 2). 
Clinical studies have shown that even individuals with a high risk for diabetes can 
significantly reduce that risk and delay the onset of type 2 diabetes by adopting a 
healthy, nutritionally balanced diet, increasing physical activity, and maintaining 
or reducing body weight (3-8). Translating this evidence into practice necessitates 
active development of efficient prevention strategies and programmes (9). To fulfil 
this need, action at a European level has been taken by launching the IMAGE project 
to unify and improve the various prevention management concepts which currently 
exist across the EU. IMAGE stands for “Development and Implementation of a 
European Guideline and Training Standards for Diabetes Prevention” and it builds 
on the results of the EU public health research project DE-PLAN “Diabetes in 
Europe-Prevention using Lifestyle, Physical Activity and Nutritional Intervention”, 
which relates to the efficient identification of  individuals at high risk for type 2 
diabetes in the community (10). The objectives of the IMAGE project are: to develop 
common evidence-based European guidelines for prevention of type 2 diabetes; to 
develop a European curriculum; and to launch an e-health training portal for the 
training of prevention managers (PM). Furthermore, the project aims to produce 
European standards for quality management of these interventions. These actions 
will form a unique Europe-wide evidence-based guidance system to systematically 
improve the prevention of type 2 diabetes in Europe (10).
Continuous quality control and evaluation are the key elements of a successful 
primary prevention programme. Thus, unified quality standards are necessary for 
systematic evaluation and reporting of prevention programmes in the EU and at a 
national level (10). Quality indicators for clinical diabetes care have been developed 
by several organizations and working groups, and have been incorporated into 
national and international guidelines. The quality management of diabetes 
prevention programmes is less developed. At present programmes often lack 
methods for systematic follow-up and evaluation, and there are no standardized 
European-level quality indicators for diabetes prevention. 
This report describes the background and the methods used in the development 
of the quality tools in the IMAGE project, and presents the European quality 
indicators for diabetes primary prevention programmes. This report focuses on 
primary prevention and is targeted at persons responsible for diabetes prevention 
at different levels within the health care system. The quality indicators are presented 
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separately for population-level and high-risk prevention strategies. The indicators 
are further divided into two categories: quality and scientific outcome evaluation 
indicators. The former constitute the minimum level of quality assurance required 
in all prevention programmes. Scientific outcome evaluation indicators enhance 
this process by enabling evaluation of a prevention programme which meets a 
scientific standard. References to measurement standards for scientific outcome 
evaluation indicators are provided. 
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2 Background 
2.1 Quality in health care 
Quality in health care can be defined as “the degree to which health services for 
individuals and populations increase the likelihood of desired health outcomes and 
are consistent with current professional knowledge” (11). However, defining the 
quality of health care is a complex and not a straightforward issue. For decades, 
experts have failed to formulate a generally applicable definition (12). Donabedian, 
a leading expert in the field of health care quality management, has stated that 
“several formulations are both possible and legitimate” (13). Thus, there are different 
perspectives on quality and different approaches to measuring and improving it 
(12). Quality in health care can be divided into different dimensions according to 
the aspects of care being assessed (14).
Evidence-based clinical guidelines are derived from the practice of evidence-
based medicine at the organizational or institutional level. However, the existence 
of clinical guidelines does not guarantee quality of care. Despite the widespread 
availability of guidelines and simple screening procedures, a considerable portion 
of the diabetic population is not properly cared for (15). Indeed, clinical guidelines 
have been shown to improve clinical practice only when introduced in the context 
of evaluation (16). As the number of published guidelines is increasing, there has 
been a need for international standards to improve the development of guidelines. 
The AGREE consortium has published an appraisal instrument for those who 
develop guidelines (17). 
2.1.1  Quality indicators in clinical care
Diabetes
Despite recommendations, quality issues or indicators are not often incorporated 
into the clinical guidelines (18). Even the most esteemed international diabetes 
guidelines commonly lack systematic quality indicators (19-22). However, the 
National Institute for Health and Clinical Excellence (NICE) (23) have published 
implementation tools including audit criteria and standards for the guidelines to 
measure organizational practice against the NICE recommendations (24).
Several projects aiming at enhancing reporting related to diabetes have been 
conducted at the European level. The European Core Indicators for Diabetes 
Mellitus (EUCID) project (2006-2007) developed 27 indicators and demonstrated 
the feasibility of data collection in different EU countries and future member states. 
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The aim of the project was to promote planning for good diabetes health status and 
diabetes care organization in each country (25).
Many consortia have developed quality indicators specifically for clinical 
diabetes care. The OECD Quality Indicator Project has published a list of nine 
health system level quality indicators for diabetes care (26, 27). In the United 
States, the Diabetes Quality Improvement Project (DQIP) has developed and 
implemented a widely accepted and comprehensive set of national measures 
for evaluation (28). A working group including participants from 15 EU/EFTA 
countries has generated an indicator set composed of 31 indicators for monitoring 
diabetes and its complications within EU/EFTA countries (29). In several European 
countries efforts have been made to implement quality indicators in diabetes care. 
In Saxony, Germany, the Saxon Diabetes Management Programme has developed 
an integrated quality management system (30). A Belgian study has produced a 
list of quality indicators for type 2 diabetes by evaluating 125 diabetes guidelines 
in five European countries (18). One group from the Netherlands provided a set of 
quality indicators for the pharmacological management of type 2 diabetes (31). In 
the field of diabetes education, the International Diabetes Federation has published 
standards including quality indicators (32, 33). 
Cardiovascular diseases
Quality measures are not incorporated into the principal European cardiovascular 
clinical guidelines (34). In the USA, quality indicators are not built into guidelines; 
however, the American Heart Association and the American College of Cardiology 
have launched an initiative to develop performance measures for health care 
providers (35). This effort is intended to promote the implementation of clinical 
evidence guidelines. These performance measures are derived from practice 
guidelines. 
2.1.2  Quality indicators in health promotion and  
  primary prevention
The OECD Quality Indicator Project has produced a set of 27 indicators covering 
primary care, prevention, and health promotion in general (36). The objectives of 
the project are to develop measures for evaluating the performance of primary care. 
Diabetes
Even though quality indicators for clinical diabetes care have been developed by 
several organizations in different countries and continents, data are scarce on 
quality management in diabetes prevention programmes. At present, programmes 
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often lack methods for systematic follow-up and evaluation. No unified European 
level quality indicators for diabetes prevention programmes have been published. 
Obesity
Many national organizations and consortia (37-39), have developed guidelines for 
prevention and management of obesity. However, only the NICE recommendations 
on obesity (40) include audit criteria, to help in the implementation of the 
guidelines, and identify measurable indicators (41).
Cardiovascular diseases
Like the diabetes guidelines, the European Society of Cardiology guidelines 
on cardiovascular disease prevention in clinical practice (22) and on diabetic 
heart disease (20) lack quality indicators. The American College of Cardiology 
Foundation/American Heart Association, in collaboration with other organizations, 
have recently published performance measures for the primary prevention of 
cardiovascular disease in adults (42) as well as a curriculum on the prevention 
of cardiovascular disease (43). The objectives of the performance measures are to 
provide practitioners and institutions with tools for measuring the quality of care 
and to identify opportunities for improvement (42). The aim of the publication of 
the performance measures is to promote the implementation of clinical evidence 
guidelines (21). The performance measure set includes 13 indicators, but specific 
performance measures for diabetes were developed in the recent work of the 
National Diabetes Quality Improvement Alliance. Previously, in Europe, a set of 
quality indicators for the prevention and management of cardiovascular disease 
in primary care was developed by experts representing nine European countries 
(44). This set of indicators incorporates 44 quality indicators, of which several are 
specifically related to diabetes (44).
2.2 Developing indicators 
2.2.1  Characteristics of quality indicators
In the field of health care, methods of measuring and evaluating performance are 
under active development. Indicators can be defined in several ways. In general, 
they are evidence-based measures that assess a particular health care structure, 
process or outcome (13). Indicators provide a quantitative base for organizations, 
planners and service providers to improve processes and care (45). They generate 
a solid and integrated overview of a variety of quality dimensions and aspects; 
however, they are not direct measures of quality, which is a multidimensional 
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phenomenon (45). Indicators are most useful when the processes and outcomes 
they relate to can be influenced by clinical interventions (46).
A good indicator is meaningful, scientifically sound and interpretable (47). 
It can be described by the following key characteristics (45): based on agreed 
definitions, a good indicator is highly specific and sensitive, valid and reliable, 
discriminates well, relates to clearly identifiable events for the user, permits useful 
comparisons and is evidence-based. 
To measure quality in a reliable way presupposes that criteria and standards 
are based on a scientifically validated fund of knowledge (48) or at least on the most 
authoritative opinion in any particular subject area (13). A valid indicator must 
be reproducible and consistent. Indicators vary in their validity and reliability. 
Validity is the degree to which the indicator measures what it is intended to 
measure, i.e. it occurs when the result of a measurement corresponds to the state of 
the phenomenon which is being measured (45). Reliability is the extent to which 
a measurement with an indicator is reproducible. Reliability is important when 
using an indicator to make comparisons among groups or within groups over time 
(45). Even though it is not possible to develop an error-free measure of quality, an 
indicator should always be tested for feasibility, reliability and validity during the 
development phase (49). When using quality indicators it should be borne in mind 
that “indicators just indicate” and that even the best indicators have limitations. 
When conclusions are drawn based on quality indicators, the limitations of the 
indicators should be taken into consideration.
2.2.2  Methods for indicator development
Indicators can be developed using systematic or non-systematic methods (49). 
Non-systematic methods are not evidence-based and indicators developed in this 
way may be less credible than those produced using systematic methods. Systematic 
methods are based on scientific evidence and guidelines (49). Often scientific 
evidence and expert opinion are combined, as in some fields evidence may be 
too scarce to be solely used. Several types of consensus methods are available for 
gathering expert opinion (49). These include consensus development conferences 
(50), the Delphi technique (49), the nominal group technique (49), the RAND 
appropriateness method (51), and iterated consensus rating procedures (49). 
13
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2.2.3  Classification of indicators
Indicators may be classified in several ways (45). In the field of prevention, the 
indicators may cover different prevention strategies such as the population-level or 
high-risk strategies, at different levels of the health care system: individual (micro), 
health system (meso) or societal (macro) level. Indicators can also be categorized 
by function, such as screening, intervention or monitoring. Generic indicators can 
be used in different kinds of settings within the health care system, while disease-
specific indicators are relevant only for a specific disease. An indicator may be either 
rate-based or sentinel. A rate-based indicator is expressed in terms of proportion 
or of rates. A sentinel indicator relates to individual events or phenomena.
The quality assessment theory by Donabedian is called the structure/process/
outcome (SPO) or the Donabedian's Triad Model (13, 52). This theory comprises 
three quality elements: structure, process and outcome. Structure describes 
the material and human resources as well as the organizational structure. This 
includes facilities, financing, equipment and personnel. Process relates to activities 
undertaken to achieve objectives, such as activities related to the giving and receiving 
of care or the implementation of interventions. Outcome describes the effect of 
care or interventions on the health status of a subject or population. Outcomes 
can be expressed in terms of ‘The five Ds’: (i) death: a bad outcome if untimely; (ii) 
disease: symptoms, physical signs, and laboratory abnormalities; (iii) discomfort: 
symptoms such as pain, nausea, or dyspnoea; (iv) disability: impaired ability in 
relation to usual activities at home, work, or in recreation; and (v) dissatisfaction: 
emotional reactions to disease and its care, such as sadness and anger (11). 
Outcome indicators can be divided into intermediate and end-result indicators 
(45). Some end-result indicators, such as survival, may only be assessed after several 
years (45). Intermediate outcome indicators describe changes in biological status 
that are closely correlated or associated with end-result outcomes (e.g. HbA1c or 
microalbuminuria in diabetes). The first two elements, structure and process, are 
indirect measures that influence the outcome. All elements are linked with each 
other. Outcome indicators seem to provide the best view of quality performance, but 
process indicators are much more sensitive and unequivocal in the measurement of 
changes in quality values (45). This structure/process/outcome approach to quality 
assessment is possible only because good structure increases the likelihood of good 
process and good process increases the likelihood of good outcome (13).
14
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3 Methodology
3.1 Process of developing indicators
Development of the IMAGE quality management system including quality 
indicators was conducted by a group of specialists representing different professional 
groups from several European countries. Members of the group have been actively 
involved in pivotal studies on diabetes prevention such as the Diabetes Prevention 
Study (DPS) and have extensive experience in the implementation of diabetes 
prevention programmes within the community. The members of the IMAGE 
Working Group and IMAGE Study Group are listed in Appendix 1.
The development of the quality management processes and quality indicators 
was based on combining evidence and expert opinion. Indicators were produced 
by the expert group in consensus meetings and further developed by a subgroup 
of experts. The working group reviewed the existing scientific evidence in the 
field. Based on that knowledge, measurement specifications were designed and the 
standards of the indicator described. Initially, 109 quality indicators were developed. 
Further selection revealed 22 key quality indicators. In addition, 20 scientific 
outcome evaluation indicators were developed. This process included detailed 
group discussions and additional literature surveys and followed the principles 
presented in Section 2.2. The final approval and selection of the indicators was 
carried out using a stepwise approval process in which the participants of the other 
IMAGE Working Groups gave their comments on the quality indicators before 
final selection.  
3.2 Defining target population
The IMAGE quality indicators are presented separately for population-level 
and high-risk prevention strategies as well as for screening for high risk. The 
population-level prevention strategy aims to improve, develop and implement 
primary prevention programmes and activities targeting the entire population. 
From a societal perspective, this is not the sole responsibility of the health care 
sector. Successful population-level prevention of diabetes involves the participation 
of different community stakeholders such as decision makers, the education 
system, the food industry, the media, urban planners, and non-governmental 
organizations. 
Screening for individuals at high risk for type 2 diabetes is essential for 
successful interventions. Different methods to screen for high-risk individuals 
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include the use of risk questionnaires, opportunistic screening and computer 
database searching. Each country and organization has to develop and introduce a 
method suitable for its local needs and resources. 
Clinical studies have consistently shown that diabetes can be prevented, or 
at least postponed, by lifestyle changes related to healthy nutrition, an adequate 
amount of physical exercise and weight reduction (3-8). In addition to lifestyle 
changes, drugs such as metformin, acarbose, orlistat and thiazolidinediones can 
reduce the relative risk of diabetes in high risk individuals with impaired glucose 
tolerance (5, 7, 53-57).The aim of the high-risk prevention strategy is to identify 
high-risk individuals and support them in adopting the lifestyle changes required 
to reduce their risk for diabetes and other vascular risk factors. 
The quality indicators were generated to be applicable to the broadest possible 
population. The definition of high-risk population used here covers all subjects at 
risk for type 2 diabetes irrespective of the screening method used to identify these 
individuals. The indicators are designed for adults, but not restricted to any specific 
age group within the adult population, and are applicable to both sexes, but may 
not be applicable to different ethnic groups. 
3.3 Classification of indicators
3.3.1  Structure, process, outcome model
The IMAGE quality indicators are classified according to the structure/process/
outcome (SPO) model (13, 52) modified so that, for practical reasons, the structure/
process indicators are presented in combination. The structure/process indicators 
constitute the quality criteria for diabetes prevention while the outcome indicators 
focus on outcome evaluation and monitoring. Thus indicators belong either to 
structure/process or outcome categories. The latter include both intermediate 
and end-result indicators as appropriate for the setting. Intermediate outcome 
indicators reflect changes in biological status and may be regarded as short-term 
outcomes (46). 
The structure/process quality indicators are aimed at internal quality assurance 
and can be used as a check-list when planning and conducting a prevention 
programme. They therefore enable comparisons between different programmes 
and also between health care providers conducting these activities.  
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3.3.2  Macro, meso and micro levels
Indicators are meant for users operating at several different levels of the health care 
system. At the macro level, indicators are developed to be utilized by national-level 
decision makers whose role it is to generate the prerequisites for diabetes/obesity 
prevention. This means, for example, representatives of the national-level health 
institutes or non-governmental organizations. 
The level of operative primary health care is called the meso level. Depending 
on the country, indicators may be used by individuals responsible for activities 
related to diabetes prevention in municipalities, health districts, health care 
centers, occupational health, the private sector or local-level non-governmental 
organizations. 
At the micro-level, the indicators are meant for use by the personnel who 
execute the actual preventative work. This may be a physician, nurse, dietician, 
physiotherapist or prevention manager. 
The IMAGE quality indicators are categorized so that the population-level 
prevention strategy indicators include both macro- and meso-level indicators. 
Screening for high-risk indicators is applicable to the meso level, and that for the 
high-risk prevention strategy indicators applicable to the meso and micro levels.
3.3.3  Quality and scientific outcome evaluation  
  indicators
The IMAGE indicators are divided into quality and scientific outcome evaluation 
indicators. Quality indicators are the minimum requirement to be considered 
when conducting prevention activities according to the level of the operator. An 
additional set of indicators, scientific outcome evaluation indicators, is provided 
for scientific evaluation purposes. Further, measurement standards for scientific 
outcome evaluation are provided. 
Table 1 presents an overview of classifications and end results of the IMAGE 
quality and outcome indicators. 
3.4 Target value assignment
In previous quality indicators projects it has been concluded that it is difficult to 
set any target values for the indicators at the European level due to different health 
care systems and varying national recommendations. A direct transfer of indicator 
target values is not always possible between countries (58). Despite this, our aim 
was to assign target values for micro-level quality indicators. This applied to the 
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Table 1. Overview of classification of IMAGE quality and outcome indicators
PREVENTION STRATEGY
Population strategy Activities aimed at promoting the health of entire population
Screening for high risk Identification of at-risk individuals
High-risk intervention 
strategy
Interventions on identified at-risk individuals
LEVEL OF HEALTH CARE OPERATOR
Macro level National-level decision makers
Meso level Operative primary health care level
Micro level Individual-level prevention work
QUALITY CRITERIA
Structure indicators Material and human resources, organizational structure
Process indicators Activities undertaken to implement intervention
QUALITY AND OUTCOME INDICATORS
Outcome indicators Effects of interventions and activities related to diabetes 
prevention
Scientific evaluation 
indicators
Outcome measures for evaluation purposes
RECOMMENDATIONS AND TOOLS
IMAGE audit tools All quality criteria and indicators, and scientific evaluation 
indicators to be used to measure current practice in diabetes 
prevention against the IMAGE guideline recommendations 
(Appendix 2)
Scientific evaluation tool The scientific evaluation indicators and corresponding 
recommendations for  measurement protocols and references 
(Appendix 3)
Data collection form An example of the content that is recommended for 
adaptation into local versions of the data collection forms at 
the micro level of diabetes prevention (Appendix 4)
high risk prevention strategy indicators for which accurate micro-level objectives 
could be extracted based on scientific data from clinical intervention studies, 
especially from the DPS study (3, 4).
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4 Results
4.1 Quality indicators for diabetes prevention
4.1.1  Population-level prevention strategies 
At the macro level, a prerequisite for the desired outcome in population-level 
prevention strategies is that policies and legislation support an environment 
favouring diabetes prevention. In addition, each country should have a national 
diabetes prevention plan in which specific prevention targets are defined. These 
targets should include consideration of the special needs of ethnic minorities and 
underprivileged socio-economic groups. Furthermore, policies and legislation 
should take into account the specific measures needed for prevention of obesity 
among children and adolescents. To enable these tasks to be accomplished, national 
health monitoring systems should provide sufficient information for conducting 
efficient surveillance. 
At the health care provider level, procedures should support health promotion 
including diabetes prevention. The health care provider should allocate sufficient 
resources to preventative work. Basic knowledge regarding population-level 
prevention of diabetes/obesity/cardiovascular diseases should be included in the 
curricula of the medical professionals employed by the health care provider. There 
should also be active collaboration between the different stakeholders active in the 
field of health promotion. 
In addition to the above-mentioned quality criteria relating to structure and 
process, a list of outcome indicators was generated during the course of the IMAGE 
work (Table 2). With these indicators at hand, decision makers can monitor and 
evaluate the quality and effectiveness of the selected population-level strategies.
Table 2. Outcome quality indicators for population-level prevention strategies at macro and 
meso levels 
MACRO-LEVEL OUTCOME INDICATORS
Proportion of population aware of diabetes and its risk factors.
Prevalence of diabetes in the population.
Percentage of the population physically inactive.
Prevalence of overweight, obesity and abdominal obesity in population.
Percentage of population following national recommendations on nutrition.
Percentage of health care costs allocated to prevention programmes.
MESO-LEVEL OUTCOME INDICATORS
Proportion of health care personnel per health care provider active in population level 
primary prevention.
Number of health promotion organizations active in population level primary prevention.
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4.1.2  Screening for high risk
Screening is an essential part of the high-risk prevention strategy. In addition, 
screening protocols can be designed so that they also support population-level 
prevention activities by increasing awareness of the disease. Different screening 
protocols should be validated and evaluated at a national level. The selected 
protocols and strategies should be implemented by the health care provider. The 
screening protocol used should contain a pathway for diagnostic procedures, as well 
as defined intervention strategies for the different subgroups (age, minority status 
etc.). The health care provider should promote validated diabetes risk assessment 
tools. Information technology systems should support the implementation of 
screening. 
Depending on the health care system, these indicators can be the responsibility 
of either macro- or meso-level operators. For this reason, the audit tool to monitor 
these quality criteria is given in Appendix 2. In addition, the indicators in Table 3 
were identified as outcome indicators for screening for high risk.
Table 3. Outcome quality indicators for screening for high risk
MESO-LEVEL OUTCOME INDICATORS
Proportion of the population screened by health care providers per year.
The percentage of identified high-risk individuals directed to diagnostic procedures.
The percentage of identified high-risk individuals directed to lifestyle interventions.
4.1.3  High-risk prevention strategies
At meso level, every screening strategy should incorporate clinical pathways in 
the organization of the health care provider to deal with individuals at risk for 
diabetes. The health care provider should support a multidisciplinary approach 
for interventions. High-risk prevention strategies should be included in the 
education of healthcare professionals. The medical record system should support 
interventions and chronic disease prevention in general. 
At micro level, the individual’s risk factor profile should be assessed at the 
beginning of the intervention process, and the motivation for behavioral changes 
explored. Structure and content of the interventions should be defined and 
individualized targets for interventions established. Plans for individual follow-
up should be defined and recorded. An audit tool (Appendix 2) includes quality 
criteria related to these elements of structure and process.
The indicators in Table 4 were identified as outcome indicators corresponding 
to the structures and processes above at meso and micro levels.
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Table 4. Outcome quality indicators for high-risk prevention strategies at meso and micro 
levels
MESO-LEVEL OUTCOME INDICATORS
Number of healthcare professionals at health care provider level qualified for interventions 
per 100.000 inhabitants.
The percentage of remitted high risk individuals participating in lifestyle interventions.
Proportion of individuals dropping out of interventions.
Proportion of high-risk individuals in interventions achieving clinically significant changes 
in risk-factors at 1 year follow-up.
Diabetes incidence rate among high-risk individuals in interventions by health care provider.
MICRO-LEVEL OUTCOME INDICATORS
Proportion of planned intervention visits completed over 1 year.
Weight change over 1 year.
Change in waist circumference over 1 year.
Change in glucose level over 1 year.
Change in the quality of nutrition over 1 year.
Change in physical activity over 1 year.
In addition to the quality indicators related to the high risk intervention strategy 
at micro-level, target values which correspond to the indicators were identified. In 
the DPS study (3), the following targets were applied: a 5% or greater reduction 
in weight, 30 minutes or more of moderate intensity daily, a dietary fat level of 
less than 30 E%, saturated fat less than 10 E%, and an intake of fiber of 15g/1000 
kcal (15g/4200 KJ) or more. These targets may be taken into consideration when 
planning micro-level diabetes prevention. However, intervention targets should be 
individualized and founded on the baseline evaluation.
4.2 Scientific outcome evaluation indicators  
 for diabetes prevention
Table 5 presents the recommended scientific evaluation indicators to be used as 
outcome measures in the scientific evaluation of a diabetes prevention programme.
To obtain reliable results, measurements and methods used in the diabetes 
prevention programmes should be standardized and valid. Table 5 provides the 
references for the recommended measurement protocols for the scientific outcome 
evaluation indicators (presented also in Appendix 3). 
The standards related to physical measurements (weight, height, waist 
circumference, blood pressure) can be found in the Feasibility of European Health 
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Examination Survey (FEHES) recommendations (62) and in the World Health 
Organization (WHO), STEPS Manual (63). The FEHES recommendations also 
include a questionnaire on smoking habits (62).
Recommendations on blood sampling and lipid measurements are available 
in the recommendations both of FEHES (62) and of the U.S. Center for Disease 
Control and Prevention (CDC) (73) which has a certification programme for lipid 
measurements. 
The WHO Laboratory Diagnosis and Monitoring of Diabetes Mellitus 2002 
document (64) provides standards for glucose measurements including the oral 
glucose tolerance test (OGTT). Diagnosis of diabetes and risk assessment is based 
on fixed cut-off points. For this reason all steps in the analytical process require 
attention (59). It is important to notice that preanalytical issues may seriously affect 
the quality of the glucose assays. Glucose is lost through glycolysis and NaF has 
been used for decades to inhibit glycolysis. In addition, ice slurry is often used to 
prevent preanalytic loss of glucose. However, new Fluoride-Citrate mixture tubes 
allow prolonged storage and transport of the samples and their adoption should 
be considered to assure a high quality measurement process (59, 60). Even though 
the expectation is that this would improve the precision of glucose measurements, 
it may also increase the number of individuals diagnosed with diabetes unless 
compensatory changes in diagnostic cut-off points are made (59).
The International Federation of Clinical Chemistry and Laboratory Medicine 
(IFCC) have published standards for HbA1c measurements (32, 33) . Major 
differences exist in commercially available insulin assays. An IFCC working group 
on the Standardization of Insulin Assays has been jointly established with the 
American Diabetes Association and is currently developing a candidate reference 
method for insulin analysis. 
There is no consensus on what constitutes adequate measurement and 
documentation of physical activity or nutrition. Dietary pattern and composition 
can be evaluated using several methods: food diary, food frequency questionnaire, 
and checklist. The selection of a method depends on availability, the cultural 
background, and the resources and level of cooperation of the high-risk individual. 
For accurate calculation of nutrient intakes, culturally specific food composition 
databases are mandatory. The quality of diet in relation to recommendations and 
dietary changes can also be assessed on the basis of frequency of consumption 
of recommendable (e.g., vegetables, fruit, whole grains) and non-recommendable 
(e.g. soft drinks, pastries) food items. 
Accurate methods to measure physical activity are pedometers and 
accelerometers. Self-reported data can be collected via interviews, diaries, and 
recalls. Assessment of physical activity should include: type of activity (e.g., 
walking, swimming), frequency (number of sessions), duration, and intensity 
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(level of physical effort). Using these four components, relative energy expenditure 
can be estimated, often referred to in terms of metabolic equivalents (METS) (61).
The European Health Interview Survey (EHIS) (74) includes standardized 
questions on use of medications. Issues related to health economic evaluation and 
the costs are presented in the IMAGE Scientific Guidelines. Quality of life should be 
measured with standardized instruments such as WHO-5 (75), SF-36 (76) , SF-12 
(77) 15-D (78) and possible translations should be certified. Treatment satisfaction 
can be measured, for example, by using the Diabetes Treatment Satisfaction 
Questionnaire (DTSQ) (79).
Table 5. Scientific outcome evaluation indicators and measurement recommendations
INDICATOR UNIT REFERENCE
Body weight, kg kg FEHES (62), WHO STEPS (63)
BMI kg/m2 FEHES (62), WHO STEPS (63)
Waist circumference cm FEHES (62), WHO STEPS (63)
Fasting and 2h OGTT glucose mmol/l WHO (59, 60, 64)
HbA1c % IFCC (32, 33)
Fasting insulin mU/l IFCC (65)
Total energy intake kcal/day IMAGE Toolkit (66, 67, 82)
Fat intake E% IMAGE Toolkit (66, 67, 82)
Saturated fat intake E% IMAGE Toolkit (66, 67, 82)
Fibre intake g/1000 kcal IMAGE Toolkit (66, 67, 82)
Physical activity METS (61, 68-72)
Fasting total HDL and LDL cholesterol mmol/l FEHES (62), CDC (73)
Fasting triglycerides mmol/l FEHES (62), CDC (73)
Systolic and diastolic blood pressure mmHg FEHES (62), WHO STEPS (63)
Smoking habits FEHES (62) 
Drug treatments EHIS (74)
Costs € IMAGE Scientific Guidelines (83)
Quality of life Score WHO-5 (75), SF-36 (76) , SF-12 (77) 
15-D (78)
Treatment satisfaction Score DTSQ (79)
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4.3 Audit tools for diabetes prevention
All the structure, process and outcome indicators developed in the IMAGE 
group are included in the IMAGE audit tool (Appendix 2). The quality criteria 
for the audit tool comprise structure and process indicators. Where possible, the 
corresponding chapter in the IMAGE scientific guidelines is identified. In addition, 
outcome quality indicators are presented for the outcome evaluation.
Audit tools were specifically developed for operators working at different levels 
in health care, i.e., at macro, meso and micro levels. The audit tools can be used 
to measure current practice in diabetes prevention against the IMAGE guideline 
recommendations. 
4.4 Micro-level data collection form 
The data collection form is an example of the content that is recommended for 
inclusion and adaptation into local versions of the data collection tools for 
the micro-level diabetes prevention. However, local needs and circumstances 
necessarily shape the final structure of the data collection form applied in different 
prevention programmes.
24
Quality and Outcome Indicators for Prevention of Type 2 Diabetes 
In Europe – IMAGE
Report 14/2010
National Institute for Health and Welfare
5 Discussion
As part of the IMAGE project, a set of quality and scientific outcome evaluation 
indicators for diabetes prevention programmes were developed along with the 
IMAGE Evidence-Based Guideline (83) and the accompanying IMAGE Toolkit for 
prevention of type 2 diabetes (82). Therefore, the indicators are closely linked to the 
guideline standards and are intended to be used in conjunction with the guidelines. 
The quality indicators are aimed to provide European decision makers, health care 
providers and health care personnel working in prevention activities with the tools 
to monitor, evaluate and improve the quality of diabetes prevention. In addition, 
standards of measurements for scientific outcome indicators were identified, with 
a view to reporting on clinical trials and effectiveness research across Europe, thus 
enabling comparisons between different study groups.
Both individual and population-level prevention strategies were taken into 
account when developing the indicators. The quality indicators were selected to 
represent different dimensions of preventative work: population-level prevention 
strategy, screening for high risk, and high-risk prevention strategy. To promote 
the usability of the indicators, they were generated to be applicable to the broadest 
possible population. The definition of high-risk population used covers all subjects 
at risk for developing type 2 diabetes irrespective of the screening method used to 
identify these individuals.
Population-level prevention strategies and macro-level quality indicators 
address the close link between type 2 diabetes, obesity and cardiovascular diseases. 
Some of the macro-level outcome indicators require data that can only be obtained 
through population-based health surveys. The Feasibility of a European Health 
Examination Survey (FEHES) collaboration (80), another EU-funded project, 
provides recommendations for organizing standardized health surveys. Further, 
population-level standardized data may be available in the future through the 
EUBIROD collaboration (81). 
Meso-level screening for high risk and high risk prevention strategy indicators 
assess quality and outcome at the health care provider level. The structure/process 
quality indicators (i.e. the quality criteria) may be used as internal quality assurance 
tools at the health care provider level when planning and conducting a prevention 
programme. The outcome quality indicators serve both as internal and external 
quality measures and enable comparisons between different programmes and 
organizations. 
Within high-risk prevention strategies, micro-level indicators address the 
quality of prevention at individual level. Target values for micro-level quality 
indicators are defined if there exists scientific evidence to support the values. These 
indicators serve as a quality tool for individual health care professionals.
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The quality indicators are intended to be used in a prospective setting, but 
may also be applicable for retrospective analysis if the quality of data collection 
allows this. Used alone, they comprise the minimum level of quality standards. 
Individuals and organizations using these measures are encouraged to involve 
the scientific evaluation perspective in their preventative work by using the 
scientific outcome evaluation indicators and related instruments described in the 
measurement standards section. High quality methodology is essential to attain 
reliable and comparable results.
Audit tools were specifically developed to measure current practice in diabetes 
prevention against the IMAGE guideline recommendations. As the responsibility 
for the implementation of the guidelines differs depending on national and 
local legislation, their implementation may need adaptation to local regulations 
and circumstances. At the micro level, individual targets should be based on 
individualized baseline evaluation.  
Even though data from the pivotal diabetes prevention studies have proved 
the efficacy of preventative interventions, less data are available on the effectiveness 
of implementation of diabetes prevention in the everyday work of primary health 
care practitioners. Thus, the development of the quality management processes 
and quality indicators was based on combining evidence and expert opinion. Some 
limitations related to the development process should be noted.
Even though the quality indicators are linked to the IMAGE Evidence-Based 
Guideline data standards, target value assignment was difficult because of lack of 
data on the general population. It should be noted that target values related to 
weight reduction, nutrition, and physical activity for micro-level quality indicators 
are drawn from the DPS study, which was conducted in obese individuals with 
impaired glucose tolerance. The working group recognizes that some of the 
indicators are based mainly on expert opinion as randomized controlled trials are 
more difficult to conduct than pharmaceutical trials, and thus the number of trials 
remains limited. 
Earlier experiences from other projects have revealed challenges in reaching 
consensus between countries with different cultural traditions and health care 
systems. A working group with representatives of 15 EU/EFTA countries has 
compiled a list of EU-level diabetes indicators (29). The work was considered 
challenging due to differences in data availability; eleven out of 15 countries 
could not provide any data. Similarly, experts in the field of cardiology have 
reported particular problems related to the development of European-level quality 
indicators for cardiovascular primary care (44). In the IMAGE project, detailed 
group discussions within the working group responsible for quality indicator 
development were followed by a stepwise approval process. 
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6 Conclusions
Parallel with the development of the IMAGE Evidence-Based Guideline and 
IMAGE Toolkit for the prevention of type 2 diabetes, a quality management 
system with quality and scientific outcome evaluation indicators and audit tools 
was developed. The indicators are presented according to the different levels of 
the health care system, and they can be used for internal quality control as well as 
for external comparison between operators by using the audit tools. These quality 
tools complement the IMAGE Evidence-Based Guideline and IMAGE Toolkit and 
the prevention manager curriculum, and will hopefully provide a useful tool for 
improving the quality of diabetes prevention in Europe. 
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Appendix 2. IMAGE Quality audit tools
MACRO-LEVEL POPULATION PREVENTION STRATEGY QUALITY CRITERIA AND QUALITY
INDICATORS
TYPE QUALITY CRITERIA CRITERIA 
MET
IMAGE 
REFERENCE
S/P
S/P
S/P
S/P
S/P
Policies and legislation support environment favouring
diabetes prevention.
A national diabetes prevention plan with specific 
prevention targets is available.
National health monitoring systems provide sufficient 
information for the surveillance of diabetes.
In all activities of diabetes prevention, ethnic minorities 
and low socio-economic groups are considered.
Policies and legislation take into account measures 
needed for prevention of obesity among children and 
adolescents.
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No
EBG
EBG
EBG
EBG
EBG
TYPE QUALITY INDICATOR DATA 
AVAILABLE
DATA 
SOURCE
O
O
O
O
O
Proportion of population aware of diabetes and its risk 
factors.
Prevalence of diabetes in the population.
Percentage of the population physically inactive.
Prevalence of overweight, obesity and abdominal 
obesity in population.
Percentage of population following national 
recommendations on nutrition.
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No
EBG = IMAGE Evidence-Based Guideline.
Data source = Identify the source of data for respective outcome indicator.
O = Outcome indicators.
S/P = Structure/Process indicators.
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MESO-LEVEL POPULATION, SCREENING AND HIGH RISK INTERVENTION STRATEGIES
QUALITY CRITERIA AND QUALITY INDICATORS
TYPE QUALITY CRITERIA CRITERIA 
MET
IMAGE 
REFERENCE
S/P Basic knowledge in population-level prevention of 
diabetes is part of the curricula of medical professionals 
working for health care provider.
Yes No
S/P Health care providers are collaborating actively with 
other players active in health promotion.
Yes No EBG
S/P Different screening protocols have been evaluated at 
national level.
Yes No EBG
S/P Validated diabetes risk assessment tools are available to 
health care providers.
Yes No EBG
S/P Information technology systems supporting the
implementation of screening are available at health 
care provider level
Yes No EBG
S/P Defined clinical pathways exist for the health care 
provider to deal with individuals at risk for diabetes.
Yes No EBG
S/P Multidisciplinary approach for interventions is supported 
by the health care provider.
Yes No EBG
S/P High-risk prevention strategies are included in the 
education of the health care professionals.
Yes No
S/P Medical record system supports interventions for chronic 
disease prevention.
Yes No
TYPE QUALITY INDICATOR DATA 
AVAILABLE
DATA 
SOURCE
O Proportion of health care personnel per health care 
provider active in population level primary prevention.
Yes No
O Number of health promotion organizations active in 
population level primary prevention.
Yes No
O Proportion of the population screened by health care 
provider per year.
Yes No
O The percentage of identified high-risk individuals 
remitted to diagnostic procedures.
Yes No
O The percentage of identified high-risk individuals 
remitted to lifestyle interventions.
Yes No
O Number of healthcare professionals at health care 
provider level qualified for interventions per 100.000 
inhabitants.
Yes No
O The percentage of remitted high-risk individuals 
participating in lifestyle interventions.
Yes No
O Proportion of individuals dropping out of interventions. Yes No
O Proportion of high-risk individuals in interventions 
achieving clinically significant changes in risk factors at 
1 year follow-up.
Yes No
O Diabetes incidence rate among high-risk individuals in 
interventions at health care provider.
Yes No
EBG = IMAGE Evidence-Based Guideline.
Data source = Identify the source of data for respective outcome indicator.
O = Outcome indicators.
S/P = Structure/Process indicators.
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MICRO-LEVEL HIGH RISK INTERVENTION STRATEGY QUALITY CRITERIA AND QUALITY
INDICATORS
TYPE QUALITY CRITERIA CRITERIA MET IMAGE 
REFERENCE
S/P Individual’s risk factor profile is assessed. Yes No IMAGE Toolkit
S/P Individual’s motivation for behavioural changes 
is discussed.
Yes No IMAGE Toolkit
S/P Structure and content of the interventions have 
been defined at individual level.
Yes No IMAGE Toolkit
S/P Individualized targets for interventions have 
been established.
Yes No IMAGE Toolkit
S/P Plan for follow-up is defined. Yes No IMAGE Toolkit
TYPE QUALITY INDICATOR DATA 
AVAILABLE
DATA SOURCE
O Proportion of planned intervention visits
completed over 1 year.
Yes No
O Weight change over 1 year. Yes No
O Change in waist circumference over 1 year. Yes No
O Change in glucose over 1 year. Yes No
O Change in the quality of nutrition over 1 year. Yes No
O Change in physical activity over 1 year. Yes No
Data source = Identify the source of data for respective outcome indicator.
O = Outcome indicators.
S/P = Structure/Process indicators.
IMAGE Toolkit = IMAGE Toolkit for the Prevention of Type 2 Diabetes in Europe.
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SCIENTIFIC EVALUATION TOOL
EVALUATION INDICATORS, UNITS OF MEASUREMENTS AND RECOMMENDED 
MEASUREMENT PROTOCOLS
INDICATOR UNIT REFERENCE
Body weight, kg kg FEHES (1), WHO STEPS (2)
BMI kg/m2 FEHES (1), WHO STEPS (2)
Waist circumference cm FEHES (1), WHO STEPS (2)
Fasting and 2h OGTT glucose mmol/l WHO (3-5)
HbA1c % IFCC (6, 7)
Fasting Insulin mU/l IFCC (8)
Total energy intake kcal/day IMAGE Toolkit (9, 10, 24) 
Fat intake E% IMAGE Toolkit (9, 10, 24) 
Saturated fat intake E% IMAGE Toolkit ((9, 10, 24) 
Fibre intake g/1000 kcal IMAGE Toolkit (9, 10, 24)
Physical activity METS (11-16)
Fasting total HDL and LDL cholesterol mmol/l FEHES (1), CDC (17)
Fasting triglycerides mmol/l FEHES (1), CDC (17)
Systolic and diastolic blood pressure mmHg FEHES (1), WHO STEPS (2)
Smoking habits FEHES (1) 
Drug treatments EHIS (18)
Costs € IMAGE Evidence-Based Guideline 
(25)
Quality of life Score WHO-5 (19), SF-36 (20) , SF-12 (21), 
15-D (22)
Treatment satisfaction Score DTSQ (23)
Appendix 3. IMAGE Scientific evaluation tool  
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RECOMMENDED CONTENTS TO BE INCLUDED AND ADAPTED IN THE LOCAL VERSIONS OF THE DATA 
COLLECTION FORMS TO SUPPORT, MONITOR AND EVALUATE MICRO-LEVEL DIABETES PREVENTION
CORE ITEMS ADDITIONAL ITEMS
1. Personal data – Personal identification – Marital status
– Education 
– Ethnicity
– Employment status 
2. Screening – Method used in screening
– Risk score type and result (if used)
– Reason for intervention 
3. Health and health
    behaviour
– Chronic diseases 
– Regular medications
– Smoking:
Never/previously/currently
– Physical activity:
Type, frequency, intensity
Method used in measuring (for 
example: interview, diary, recall, 
pedometers, accelerometers)
– Nutrition:
Dietary pattern: consumption of 
vegetables, fruits, spreads and oil, 
bread and cereal (whole / refined 
grain), sweets, beverages, alcohol e.g.
Method used in measuring (for 
example: food diary, food frequency 
questionnaire or checklist)
– Family history of diabetes and
   CVD
How often, products used
Work-related, commuting, leisure
Energy proportion (E%) of fat, 
saturated and trans fat, dietary 
fiber (g / day, g / 1000 kcal),  total 
energy, alcohol (g, E%), added 
sugar (g, E%)
4. Clinical data 
    (measured) 
– Body weight
– Body height
– Waist circumference
– Fasting glucose
– Systolic and diastolic blood pressure
– 2 hour OGTT glucose
– HbA1c
– Lipids (total, LDL, HDL cholesterol
   and triglycerides)
– Additional measures (fasting 
   insulin etc)
5. Content of the 
     intervention
– Type of intervention (group, 
   individual etc.)
– Frequency, duration and other details
– Targets for the intervention: 
Weight, diet, smoking, physical activity
– Reinforcement
6.  Success of the
     intervention 
– Adherence (proportion of planned 
   intervention visits completed)
– Changes in: health and health 
   behavior (item 3) and clinical data 
   (item 4)
– The Diabetes Treatment 
   Satisfaction Questionnaire: DTSQ
– Health related quality of life
7. Maintenance – Plans how to sustain possible lifestyle
   changes after intervention
Appendix 4. IMAGE Micro-level data 
collection form  
